HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Neurology34 papers

Paraneoplastic sensorimotor neuropathy

Last edited: 4/15/2026

Overview

Paraneoplastic sensorimotor neuropathy refers to a neurological disorder characterized by muscle weakness and sensory disturbances secondary to an underlying malignancy, often without direct infiltration of the nervous system 1.

Diagnosis

  • Clinical presentation of asymmetric sensorimotor symptoms 1.
  • Electromyography (EMG) and nerve conduction studies showing axonal or demyelinating changes 1.
  • Comprehensive cancer screening to identify underlying malignancy 1.
  • Exclusion of other causes of neuropathy through detailed history and physical examination 1.

    • Management

  • Discontinue offending agents if identified (e.g., sulphasalazine) 1.
  • Symptomatic treatment with corticosteroids or intravenous immunoglobulin (IVIG) for acute exacerbations 1.
  • Supportive care including physical therapy and occupational therapy 1.

    • Special Populations

  • No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.

    • Key Recommendations

  • Conduct thorough malignancy screening in patients presenting with paraneoplastic sensorimotor neuropathy 1 (Evidence: Expert opinion).
  • Consider discontinuation of suspected drug (e.g., sulphasalazine) if a paraneoplastic neuropathy is suspected to be drug-induced 1 (Evidence: Weak).
  • Employ symptomatic treatments such as corticosteroids or IVIG for managing acute exacerbations of neuropathy 1 (Evidence: Weak).

    • References

    1 Price TR. Sensorimotor neuropathy with sulphasalazine. Postgraduate medical journal 1985. link

    Original source

    1. [1]
      Sensorimotor neuropathy with sulphasalazine. — Price TR Postgraduate medical journal (1985)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG